E1A signaling to p53 involves the p19(ARF) tumor suppressor

Genes and Development

Volumn 12, Issue 15, 1998, Pages 2434-2442

  De Stanchina, Elisa ^a   McCurrach, Mila E ^a   Zindy, Frederique ^b   Shieh, Sheau Yann ^c   Ferbeyre, Gerardo ^a   Samuelson, Andrew V ^a   Prives, Carol ^c   Roussel, Martine F ^b   Sherr, Charles J ^b   Lowe, Scott W ^a  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

E1A signaling; p19(ARF) tumor suppressor; p53

Indexed keywords

PROTEIN P53; RETINOBLASTOMA PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHEMOSENSITIVITY; DNA DAMAGE; EXPRESSION VECTOR; GENE EXPRESSION; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; ANIMALIA;

EID: 0032146795     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.12.15.2434     Document Type: Article

References (57)

1. Andree, H.A., C.P. Reutelingsperger, R. Hauptmann, H.C. Hemker, W.T. Hermens, and G.M. Willems. 1990. Binding of vascular anticoagulant alpha (VAC alpha) to planar phospholipid bilayers. J. Biol. Chem. 265: 4923-4928.
2. Barak, Y., T. Juven, R. Haffner, and M. Oren. 1993. mdm2 expression is induced by wild-type p53 activity. EMBO J. 12: 461-468.
3. Barak, Y., E. Gottlieb, T. Juvengershon, and M. Oren. 1994. Regulation of mdm2 expression by p53: Alternative promoters produce transcripts with nonidentical translation potential. Genes & Dev. 8: 1739-1749.
4. Debbas, M. and E. White. 1993. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes & Dev. 7: 546-554.
5. DeCaprio, J.A., J.W. Ludlow, D. Lynch, Y. Furukawa, J. Griffin, H. Piwnica-Worms, C.M. Huang, and D.M. Livingstone. 1988. SV40 large T antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 54: 275-283.
6. DeGregori, J., G. Leone, A. Miron, L. Jakoi, and J.R. Nevins. 1997. Distinct roles for E2F proteins in cell growth control and apoptosis. Proc. Natl. Acad. Sci. 94: 7245-7250.
7. Donehower, L.A., M. Harvey, B.L. Slagle, M.J. McArthur, C.A. Montgomery, J.A. Butel, and A. Bradley. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-220.
8. Dyson, N., P.M. Howley, K. Munger, and E. Harlow. 1989. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243: 934-937.
9. El Deiry, W.S., T. Tokino, V.E. Velculescu, D.E. Levy, R. Parsons, J.M. Trent, D. Lin, W.E. Mercer, K.W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
10. Evan, G.I., A.H. Wyllie, C.S. Gilbert, T.D. Littlewood, H. Land, M. Brooks, C. Waters, L.Z. Penn, and D.C. Hancock. 1992. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119-128.
11. Flint, J. and T. Shenk. 1997. Viral transactivating proteins. Annu. Rev. Genet. 31: 177-212.
12. Graeber, T.G., J.F. Peterson, M. Tsai, K. Monica, A.J. Fornace, and A.J. Giaccia. 1994. Hypoxia induces accumulation of p53 protein, but activation of a G(1)-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol. Cell. Biol. 14: 6264-6277.
13. Greenblatt, M.S., W.P. Bennett, M. Hollstein, and C.C. Harris. 1994. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancel Res. 54: 4855-4878.
14. Griffiths, S.D., A.R. Clarke, L.E. Healy, G. Ross, A.M. Ford, M.L. Hooper, A.H. Wyllie, and M. Greaves. 1997. Absence of p53 permits propagation of mutant cells following genotoxic damage. Oncogene 14: 523-531.
15. Haber, D.A. 1997. Splicing into senescence: The curious case of p16 and p19ARF. Cell 91: 555-558.
16. Harlow, E., B.R. Franza, Jr., and C. Schley. 1985. Monoclonal antibodies specific for adenovirus early region 1A proteins: extensive heterogeneity in early region 1A products. J. Virol. 55: 533-546.
17. Harper, J.W., G.R. Adami, N. Wei, K. Khandan, and S.J. Elledge. 1993. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816.
18. Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299.
19. Hermeking, H. and D. Eick. 1994. Mediation of c-myc induced apoptosis by p53. Science 265: 2091-2093.
20. Jacks, T., L. Remington, B.O. Williams, E.M. Schmitt, S. Halachmi, R.T. Bronson, and R.A. Weinberg. 1994. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4: 1-7.
21. Kamijo, T., F. Zindy, M.F. Roussel, D.E. Quelle, J.R. Downing, R.A. Ashmun, G. Grosveld, and C.J. Sherr. 1997. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91: 649-659.
22. Kamijo, T., J.S. Weber, G. Zambetti, F. Zindy, M.F. Roussel, and C.J. Sherr. 1998. Interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. 95: 8292-8297.
23. Kastan, M.B., O. Onyekwere, D. Sidransky, B. Vogelstein, and R.W. Craig. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51: 6304-6311.
24. Ko, L.J. and C. Prives. 1996. p53: Puzzle and paradigm. Genes & Dev. 10: 1054-1072.
25. Kubbutat, M.H., S.N. Jones, and K.H. Vousden. 1997. Regulation of p53 stability by Mdm2. Nature 387: 299-303.
26. Lane, D.P. and L.V. Crawford. 1979. T antigen is bound to a host protein in SV40-transformed cells. Nature 278: 261-263.
27. Levine, A.J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
28. 1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes & Dev. 10: 934-947.
29. Linzer, D.I.H. and A.J. Levine. 1979. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40 transformed cells and uninfected embryonal carcinoma cells. Cell 17: 43-52.
30. Livingstone, L.R., A. White, J. Sprouse, E. Livanos, T. Jacks, and T.D. Tlsty. 1992. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70: 923-935.
31. Lowe, S.W. and H.E. Ruley. 1993. Stabilization of the p53 tumor suppressor is induced by adenovirus E1A and accompanies apoptosis. Genes & Dev. 7: 535-545.
32. Lowe, S.W., H.E. Ruley, T. Jacks, and D.E. Housman. 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 954-967.
33. Lowe, S.W., S. Bodis, A. McClatchey, L. Remington, H.E. Ruley, D. Fisher, D.E. Housman, and T. Jacks. 1994a. p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810.
34. Lowe, S.W., T. Jacks, D.E. Housman, and H.E. Ruley. 1994b. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc. Natl. Acad. Sci. 91: 2026-2030.
35. Maki, C.G., J.M. Huibregtse, and P.M. Howley. 1996. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res. 56: 2649-2654.
36. McCurrach, M.E., T.M. Connor, C.M. Knudson, S.J. Korsmeyer, and S.W. Lowe. 1997. bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc. Natl. Acad. Sci. 94: 2345-2349.
37. Pomerantz, J., N. Schreiber-Agus, N.J. Liegeois, A. Silverman, L. Alland, L. Chin, J. Potes, K. Chen, I. Orlow, H.W. Lee, C. Cordon-Cardo, and R.A. DePinho. 1998. The INK4a tumor suppressor gene product, p19ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713-723.
38. Quelle, D.E., F. Zindy, R.A. Ashmun, and C.J. Sherr. 1995. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000.
39. Querido, E., J.G. Teodora, and P.E. Branton. 1997. Accumulation of p53 induced by the adenovirus E1A protein requires regions involved in the stimulation of DNA synthesis. J. Virol. 71: 3526-3533.
40. Ross, W.E. and M.O. Bradley. 1981. DNA double-stranded breaks in mammalian cells after exposure to intercalating agents. Biochim. Biophys. Acta 654: 129-134.
41. Samuelson, A.V. and S.W. Lowe. 1997. Selective induction of p53 and chemosensitivity in RB-deficient cells by E1A mutants unable to bind the RB-related proteins. Proc. Natl. Acad. Sci. 94: 12094-12099.
42. Serrano, M., G.J. Hannon, and D. Beach. 1993. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707.
43. Serrano, M., A.W. Lin, M.E. McCurrach, D. Beach, and S.W. Lowe. 1997. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88: 593-602.
44. Shieh, S.Y., M. Ikeda, Y. Taya, and C. Prives. 1997. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325-334.
45. Siliciano, J.D., C.E. Canman, Y. Taya, K. Sakaguchi, E. Appella, and M.B. Kastan. 1997. DNA damage induces phosphorylation of the amino terminus of p53. Genes & Dev. 11: 3471-3481.
46. Symonds, H., L. Krall, L. Remington, M. Saenzrobles, S. Lowe, T. Jacks, and T. Vandyke. 1994. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78: 703-711.
47. Wagner, A.J., J.M. Kokontis, and N. Hay. 1994. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/ cip1. Genes & Dev. 8: 2817-2830.
48. Weinberg, R.A. 1995. The retinoblastoma protein and cell cycle control. Cell 81: 323-330.
49. Wcrness, B.A., A.J. Levine, and P.M. Howley. 1990. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248: 76-79.
50. Whyte, P., K.J. Buchkovich, J.M. Horowitz, S.H. Friend, M. Raybuck, R.A. Weinberg, and E. Harlow. 1988a. Association between an oncogene and an anti-oncogene: The adenovirus E1A proteins bind to the retinoblastoma gene product. Nature 334: 124-129.
51. Whyte, P., H.E. Ruley, and E. Harlow. 1988b. Two regions of the adenovirus early region 1A proteins are required for transformation. J. Virol. 62: 257-265.
52. Whyte, P., N.M. Williamson, and E. Harlow. 1989. Cellular targets for transformation by the adenovirus E1A proteins. Cell 56: 67-75.
53. Wu, X., J.H. Bayle, D. Olson, and A.J. Levine. 1993. The p53-mdm-2 autoregulatory feedback loop. Genes & Dev. 7: 1126-1132.
54. Xiong, Y., G.J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach. 1993. p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-705.
55. Yin, Y., M.A. Tainsky, F.Z. Bischoff, L.C. Strong, and G.M. Wahl. 1992. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70: 937-948.
56. Zhang, Y., Y. Xiong, and W.G. Yarbrough. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725-734.
57. Zindy, F., C.M. Eischen, D.H. Randle, T. Kamijo, J.L. Cleveland, C.J. Sherr, and M.F. Roussel. 1998. MYC-induced immortalization and apoptosis targets the ARF-p53 pathway. Genes & Dev. (this issue).